People
45,215Biopharmaceutical company builder and partner in Sofinnova’s Biovelocita strategy. He leads Forth Therapeutics and previously served as founding CEO of Alchemab and CEO of Creabilis.
David Evans is now a Partner in Sofinnova’s Crossover Strategy, which he joined in June2026. Sofinnova’s own biography and July13,2026 appointment release confirm he previously served as Roche Venture Fund investment director, latterly senior investment director. Earlier Roche work included global data science for neuroscience and rare diseases. His existing Sofinnova role is preserved. Exact Roche departure day is unknown.
Biotechnology company builder, partner in Sofinnova’s Biovelocita strategy and CEO of BioClec, which develops microglia-targeted therapies for Alzheimer’s disease.
Antoine Papiernik is a Noema Pharma board member and Chairman and Managing Partner of Sofinnova Partners. He joined Sofinnova in1997 and has backed life-sciences companies through its Capital Funds. Sofinnova founded and seed-financed Noema; the firm’s investment is distinct from any personal check by Papiernik.
Richard J. Thompson is Professor of Molecular Hepatology at King’s College London and a paediatric liver disease specialist. He researches the genetic basis of liver disorders and advises Integra Therapeutics on clinical applications. The middle initial is established by his university publication record.
PfizerVentures primarypublished affiliation: Vice President, WWBD / Partner. Jiaping Gu, PhD, is a Partner at Pfizer Ventures and Vice President, Worldwide Business Development. Jiaping is responsible for identifying, evaluating, making and managing equity investments aligned with the future scientific and strategic directions of Pfizer. He manages Pfizer’s venture investments in early-stage biotechnology companies, with a particular focus on opportunities in China. Jiaping brings 10+ years of investment experiences in both public and private life science companies. Prior to Pfizer Ventures, Jiaping is a Partner at Takeda Ventures, where he was responsible for sourcing and executing investments aligned with Takeda’s R&D strategy and managing Takeda’s equity portfolio. Prior to Takeda Ventures, Jiaping was Vice President at Hillhouse Investment, where he was a member of the Bioventure team covering private stage biotech investments in the US and Europe. Previously he has more than 10 years of research experiences focusing on neurodegeneration in the pharmaceutical industry and academic institutions. Jiaping earned his PhD in Neuroscience from Rutgers University and received his BS in Biological Sciences from Tsinghua University in China.
General partner at Backstage Capital with prior investment experience at #ANGELS, Village Capital and Techstars, and banking and startup operating experience.
Founder of Backstage Capital, investing in technology companies led by underrepresented founders; announced a transition to a chair and advisory role after leading the firm.
Novoron Bioscience COO, co-founder and director, with experience in financial planning, startup funding and business development.
Novoron Bioscience CEO, co-founder and board chairman; UC San Diego-trained biomedical scientist researching LDL receptor biology in neurological injury and disease.
Robert Eastlack serves Novoron Bioscience as Spinal Cord Injury Advisory Council Member.
Bryn Martin serves Novoron Bioscience as Spinal Cord Injury Advisory Council Member.
Linda Jones serves Novoron Bioscience as Spinal Cord Injury Advisory Council Member.
Michael G. Fehlings serves Novoron Bioscience as Spinal Cord Injury Advisory Council Member.
Miguel de los Rios serves Novoron Bioscience as Scientific Advisory Board Member.
Rivka Kreitman serves Novoron Bioscience as Scientific Advisory Board Member.
James Whisstock serves Novoron Bioscience as Scientific Advisory Board Member.
Jeff Goldberg serves Novoron Bioscience as Scientific Advisory Board Member.
Kurt Brunden serves Novoron Bioscience as Scientific Advisory Board Member.
Jennifer Rauch serves Novoron Bioscience as Scientific Advisory Board Member.
Lawrence Goldstein serves Novoron Bioscience as Scientific Advisory Board Member.
Novoron Bioscience CFO supporting financial strategy and business development; life sciences finance adviser with mechanical engineering and business administration training.
Novoron Bioscience specialist in nonclinical translation and business development; neuroscientist with prior regenerative medicine and nonclinical development leadership experience at Athersys.
Drug discovery and development specialist at Novoron Bioscience; medicinal chemist with prior chemistry leadership experience at Artizan Biosciences and Viamet Pharmaceuticals.
SV Health Investors investor relations director supporting fundraising for its biotechnology and dementia strategies; previously worked in private equity fundraising.
SV Health Investors UK chief financial officer and partner, supporting European fund finance operations including the Dementia Discovery Funds.
Dementia Discovery Fund scientific adviser and drug discovery executive; joined GSK in 2025 after scientific leadership roles at BenevolentAI and Pfizer.
Dementia Discovery Fund scientific adviser with translational drug research experience at Astex, SuperGen and Onyx Pharmaceuticals.
Dementia Discovery Fund scientific adviser with research strategy experience at Alzheimer's Research UK and the MS Society, and cancer biology and immunology training.
Dementia Discovery Fund scientific adviser and neuroscience research executive; joined Biogen in 2025 after research leadership roles at NeuroSolutions, Lundbeck and Servier.
Dementia Discovery Fund scientific adviser with pharmaceutical neuroscience and molecular imaging leadership experience, including Bristol Myers Squibb, Biogen and Merck.
Dementia Discovery Fund scientific adviser and neuroscientist with neurodegeneration research and development experience at Janssen, Novartis and Merck.
Dementia Discovery Fund scientific adviser and pharmacologist with academic and pharmaceutical leadership experience in central nervous system drug discovery.
Dementia Discovery Fund scientific adviser and neuroscientist with experience leading Alzheimer's Association research initiatives and international dementia science programs.
Dementia Discovery Fund scientific adviser and pharmacologist with research and drug development experience in neurodegeneration, pain and migraine at Eli Lilly.
Dementia Discovery Fund scientific adviser with biochemistry training and experience directing health and life sciences initiatives at Gates Ventures. Niranjan Bose is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Managing Director, Health and Life Sciences, Gates Ventures, LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment. The ADDF biography identifies him as GatesVentures managing director for Health and LifeSciences and science adviser to BillGates, following service at the GatesFoundation; these are distinct institutions. Niranjan Bose is managing director of Health & Life Sciences Strategy at Gates Ventures LLC and scientific adviser to Bill Gates, as confirmed by the March 2026 ADDF Alzheimer’s Insights Summit biography. He joined the office in August 2014 after working at the Gates Foundation between 2007 and 2014. He also serves as interim executive director of the Alzheimer’s Disease Data Initiative.
Dementia Discovery Fund scientific adviser and neuroscientist with pharmaceutical clinical development and venture investment experience, including Pfizer Ventures. PfizerVentures primarypublished affiliation: Vice President, WWBD / Partner. Rana Al-Hallaq, PhD is Partner and Head of Operations at Pfizer Ventures and Vice President, Worldwide Business Development. Rana is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Autifony Therapeutics, Biograph55, Enara Bio, Montis Biosciences, Nucleome Therapeutics, ReCode Therapeutics, RefleXion Medical, TwoStep Therapeutics, and Vivet Therapeutics. Her prior investment responsibilities include Cortexyme, Jnana Therapeutics, Mitokinin, Triplet Therapeutics, and VectivBio. She is also responsible for managing investments in the Dementia Discovery Funds, the Health Enterprise Partners Fund, and the Wellington Venture Investments Fund. Rana serves as Vice Chair on the New York BIO Board of Directors. Prior to her current role, Rana was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas. She began her training as a research fellow at the National Institutes of Health. Rana graduated Summa Cum Laude and Phi Beta Kappa with a BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.
Executive assistant on the Dementia Discovery Fund team since 2023, with prior financial services operations experience at BNY Mellon.
Executive assistant supporting Dementia Discovery Fund's London partners; previously supported LifeArc leadership and worked in healthcare investor relations.
Dementia Discovery Fund venture partner and Endlyz co-founder and CEO; biochemist with prior Lilly neurodegeneration drug discovery experience.
Dementia Discovery Fund venture partner and neurologist with neuroscience clinical development experience; formerly chief medical officer at Alector and Passage Bio.
Dementia Discovery Fund venture partner with neuroscience drug discovery experience; formerly chief scientific officer at Alzheimer's Research UK and a Pfizer research leader.
Dementia Discovery Fund venture partner specializing in neurological clinical development; previously led neurology medical strategy at IQVIA. Lynne Hughes is a scientific adviser to NeuroVision Imaging’s BrainHealth programme. Former VP and Global Head, Medical Strategy, Neurology at IQVIA, Dr. Hughes is currently a member of the NIA-NIH task force for recruitment into Alzheimer’s trials and of the G7 & G20 World Dementia Councils. She is also co-chair of the DAVOS (DAC) taskforce for expediting clinical Alzheimer’s trials.
Dementia Discovery Fund venture partner and neurologist with academic and pharmaceutical research experience in protein aggregation and neurodegenerative disease. Damian Crowther is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Having trained in clinical neurology in Oxford, Nottingham and Cambridge, Damian then lead a neuroscience research group at the Cambridge Institute for Medical Research and Department of Genetics, University of Cambridge. Damian moved to industry in 2015, becoming the Director and Head of Early R&D with AstraZeneca Neuroscience. He is Entrepreneur in Residence at Cambridge Innovation Capital and Venture Partner at SV’s Dementia Discovery Fund. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check. Damian Crowther co-founded TRIMTECH and leads research. A neurologist and neuroscience entrepreneur, he previously led early discovery at AstraZeneca Neuroscience and conducted academic research at Cambridge. His entrepreneur-in-residence work includes DDF, CIC and Oxford Science Enterprises; he also co-founded GPnotebook. Damian Crowther is listed by Cambridge Innovation Capital as entrepreneur in residence. Life-sciences entrepreneur in residence with clinical neurobiology and early neuroscience drug-discovery experience, including AstraZeneca; existing TRIMTECH and other affiliations remain preserved. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.
Dementia Discovery Fund associate with Cambridge research experience in inflammation and Parkinson's disease; promoted from senior analyst in 2025.
Gradiant in Residence supporting Dementia Discovery Fund investment work and partnerships; also a strategic planning executive at Gradiant in South Korea.
Dementia Discovery Fund associate and neuroscientist; previously a Bloomberg Intelligence analyst covering neurodegeneration, neuropsychiatry and rare disease companies.
Dementia Discovery Fund vice president and neuroscientist with experience in Alzheimer's disease research and pharmaceutical strategy consulting.
Director of Translational Sciences at Minoryx, with a PhD in Human Molecular Genetics from the University of Barcelona and research experience in rare neurological and mitochondrial diseases. Her full surname appears as Laura Rodriguez-Pascau in the Minoryx-affiliated author list of the NEXUS interim analysis. She is distinct from Invivo Partners investor Laura Rodríguez.
Adviser to Two Bear Capital; MD Anderson oncologist and immunologist studying cancer immunotherapy and resistance to immune checkpoint treatment.
Adviser to Two Bear Capital and Chief Customer Experience Officer at Pure Storage; previously a Cisco services executive.
Senior Biopharmaceutical Adviser to Two Bear Capital; formerly Executive Director of Biologics Discovery at Amgen.
Adviser to Two Bear Capital and CEO of Evolve Biologics; previously CEO of Dendreon Pharmaceuticals.
Adviser to Two Bear Capital; MD Anderson immunologist and Nobel laureate whose research contributed to cancer immune checkpoint therapies.
Head of Community Engagement at Two Bear Capital; previously founded and led Montana's Frontier Angels investor network.
Executive Assistant supporting Two Bear Capital's Menlo Park team, with previous work in investment and asset management.
Executive Assistant supporting Two Bear Capital operating partners, with prior executive support experience in technology and pharmaceuticals.
Head of Research at Two Bear Capital; UC San Diego-trained neuroscientist with experience in therapeutic development and medical affairs.
Partner and Head of Operations at Two Bear Capital, focused on financial management and portfolio services; previously worked at Sequoia Capital.
Partner and Head of Capital Formation at Two Bear Capital; previously led capital formation at SOSV and worked with institutional investors at BlackRock and other firms.
Operations Manager at Two Bear Capital responsible for internal processes, budgets and day-to-day operations.
Executive Assistant to Two Bear Capital founder Mike Goguen, with experience supporting executive operations at startups.
Chief Information Officer at Two Bear Capital, leading AI, data and analytics strategy; previously held solutions engineering leadership roles at StarTree and Cockroach Labs.
Operating Associate at Two Bear Capital supporting life sciences portfolio companies and AI implementation; former healthcare consultant and biotechnology business development professional.
Operating Partner for enterprise companies at Two Bear Capital; former revenue leader at StarTree and Cockroach Labs.
Head of Strategic Talent at Two Bear Capital with experience recruiting and developing teams in technology, healthcare and professional services.
Partner and Head of Platform at Two Bear Capital, leading portfolio support and founder programs; Babson College business communication professor and executive coach.
Partner at Two Bear Capital with healthcare investment banking experience and prior advisory work for Emerson Collective's health investing team.
Venture Partner at Two Bear Capital; former Leerink Partners research director and healthcare investment strategist.
Partner at Two Bear Capital focused on therapeutics, diagnostics, tools and medical devices, including oncology and neurodegeneration.
Associate at Two Bear Capital focused on AI, quantum computing and cybersecurity, with applied mathematics and data analysis experience.
Partner at Two Bear Capital; cybersecurity specialist, former Google Chrome security team leader and co-founder of Divergent Security.
Founder and Managing Partner of Two Bear Capital; previously a Sequoia Capital investor with engineering experience in technology and life sciences.
Principal at Two Bear Capital investing in drug discovery platforms; Harvard-trained scientist with single-cell genomics and biotechnology strategy experience.
Principal at Two Bear Capital focused on therapeutics; MIT-trained neuroscientist with research experience in Alzheimer's disease models and tissue imaging.
Partner at Two Bear Capital investing in life sciences, AI and cybersecurity; formerly COO and CTO of Adaptive Biotechnologies.
Associate at RTK Group; holds a PhD according to the firm's current public team page.
Senior Associate in Operations at RTK Group.
Senior Associate in Finance at RTK Group.
Founding Partner of RTK Group, which she founded in December 2019; physician and Tufts University infectious disease specialist with clinical research and biotechnology advisory experience.
Computational biologist and adviser to Unravel Biosciences; Harvard and Dana-Farber researcher working on gene regulatory networks and health data.
Psychiatrist and adviser to Unravel Biosciences; Massachusetts General Hospital researcher focused on bipolar disorder, depression and clinical trials.
Neuroscientist and adviser to Unravel Biosciences, with prior research leadership roles at Harvard and UC Santa Barbara.
Adviser to Unravel Biosciences and co-founder and CEO of Aptabridge Therapeutics, with experience leading biotechnology operations and drug development.
Co-founder and adviser to Unravel Biosciences; Tufts University biologist studying developmental biology, regeneration and bioelectric signaling.
Co-founder and adviser to Unravel Biosciences; Donald E. Ingber is founding director of Harvard's Wyss Institute and a researcher in mechanobiology and Organ Chip technology.
Program Manager at Unravel Biosciences coordinating therapeutic development projects and partnerships across its rareSHIFT portfolio.
Business Development Manager at Unravel Biosciences supporting Predictable Medicine and rareSHIFT partnerships with industry, patient foundations and healthcare institutions.
Senior Computational Biologist at Unravel Biosciences, focusing on explainable computational models and biological network analysis.
Data Scientist at Unravel Biosciences working on data processing, visualization and reporting; previously an intensive care nurse.
Research Associate at Unravel Biosciences, working on tadpole drug screens and clinical study coordination for rareSHIFT.
Lead Computational Scientist at Unravel Biosciences; computer scientist developing the company's computational architecture, with prior Dell/EMC engineering experience.
Therapeutic Portfolio Director at Unravel Biosciences, coordinating computational and experimental drug discovery; previously developed Xenopus screening methods at the Wyss Institute.
Computer Engineer at Unravel Biosciences, working on computational drug screening and patient stratification, with prior healthcare software experience at Intermountain Healthcare.
Chief Medical Officer of Unravel Biosciences and Managing Director of RTK Group; physician and former Azurity Pharmaceuticals CEO with industry, FDA and healthcare investment banking experience.
Co-founder and Chief Scientific Officer of Unravel Biosciences; molecular biologist with prior Wyss Institute and SRI International research experience.
Co-founder and CEO of Unravel Biosciences; bioengineer and former Wyss Institute lead engineer working on drug discovery, disease models and laboratory automation.
PLD Space board director and CDTI technology-company capitalization specialist. Quibim’s own public board directory identifies the native same-name person as Head of Capitalization of Technology Companies at CDTI; PLD Space’s own published event post independently identifies him with CDTI. Board affiliation is distinct from employment.
Apollo Health Ventures current own career biography: Jeanne is a member of the Advisory Board at apollo.vc With over 35 years of expertise in the pharmaceutical industry, Jeanne has held various managerial positions encompassing research and development, commercial operations, business development, and venture investment. During the last decade, Jeanne served as the Vice President of venture investment within Johnson & Johnson's corporate venture fund, Johnson & Johnson Innovation - JJDC. Before her tenure at JJDC, she worked as a director in the business development team at GlaxoSmithKline. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.
Adviser to BEVC; life-science entrepreneur with experience in genomics, diagnostics and therapeutics.
Adviser to BEVC; UC Berkeley molecular biologist and biotechnology company founder.
Adviser to BEVC with experience in technology investing, semiconductors and entrepreneurship; co-founder of Congruent Ventures.
Adviser to BEVC; cellular neurobiologist and former UCSF and QB3 leader supporting scientific entrepreneurship.
Adviser to BEVC; UC Berkeley biochemist and Nobel laureate for CRISPR genome-editing research.
Adviser to BEVC; Stanford professor working on computational cancer genomics and biomedical data science.
Adviser to BEVC with expertise in computing, data science and artificial intelligence.
Adviser to BEVC; cleantech investor and materials-recycling entrepreneur.
Fractional Chief Financial Officer at BEVC with experience in venture capital finance and operations, including DCVC and Venrock.
Venture Partner at BEVC with venture investing and operating experience in climate, industrial and healthcare technology.
Founding Advisor to BEVC, UC Berkeley professor and biotechnology entrepreneur working on gene and stem-cell therapies.
Co-founder of BEVC with experience in venture investing and company creation, including Kleiner Perkins and GE Ventures.
Co-founder of BEVC; bioengineer with life-science investing and operating experience, including B Capital, Red Tree VC and InterVenn.
Investor at BEVC with a PhD in chemical engineering and experience in materials science, semiconductors and industrial chemistry.
General Partner at Two Bear Capital and Montara Therapeutics board member; Stanford-trained structural biologist with genomics, data science and software engineering experience.
Eric Karran is listed by Montara Therapeutics as Neuroscience Advisor.
Joseph Arena is listed by Montara Therapeutics as Regulatory Affairs Advisor.
John Burkhardt is listed by Montara Therapeutics as Toxicology Advisor.
Stevan Djuric is listed by Montara Therapeutics as Medicinal Chemistry Advisor.
Shawn Johnstone is listed by Montara Therapeutics as Synthetic Chemistry Advisor.
Michael Keiser is listed by Montara Therapeutics as SAB Member.
Miratul Muqit is listed by Montara Therapeutics as SAB Member.
Ziyang Zhang is listed by Montara Therapeutics as SAB Member.
Martin Kampmann is listed by Montara Therapeutics as Co-Scientific Founder & SAB Member.
Max Lebovitz is listed by Montara Therapeutics as Vice President, Business Operations.
Rishi Rakhit is listed by Montara Therapeutics as Vice President, Pharmacology.
Dirk Landgraf is listed by Montara Therapeutics as Chief Business Officer.
Zachary Hill is listed by Montara Therapeutics as Chief Technology Officer.
David Michelson is listed by Montara Therapeutics as Chief Medical Officer.
Nicholas T. Hertz is listed by Montara Therapeutics as Founder, President and Chief Executive Officer.
SV Health Investors venture partner, Autifony Therapeutics co-founder and independent chair of Teitur Trophics; neuroscientist specializing in ion channels and neuropsychiatric drug discovery.
Operations Manager at KdT Ventures, US Air Force veteran and venture/startup operations professional.
Head of Talent at KdT Ventures, with a PhD in molecular biophysics and experience in life-science executive recruiting.
Head of Operations at KdT Ventures with experience in administration, flight operations and team management.
Managing Partner at KdT Ventures and former startup attorney.
Principal at KdT Ventures and physician-scientist with experience in molecular imaging, translational oncology and technology commercialization.
Associate at KdT Ventures with a PhD in pharmacology and research experience in receptor signaling and cellular trafficking.
Mary Zhucui is listed by SOSV as Risk Controller.
Jenny Zhou is listed by SOSV as Sourcing Assistant.
Qiyu Wu is listed by SOSV as Operations Director.
Vitaly Vyazovsky is listed by SOSV as Creative Director.
Avra van der Zee is listed by SOSV as General Partner. Board positions Avra has board experience in various early-stage companies and currently serves as Chairperson of the Board at Made of Air. Career 2023 – Chairperson of the Board, Made of Air 2022 – 2023 Board Director, Made of Air 2021 – Chief Operating Officer, Elemental Excelerator 2020 – Strategic Advisor & Board Director, Various early-stage companies 2020 – 2021 VP, Strategy and Policy, Superpedestrian 2018 – 2020 Director, Global Market Entry, Uber 2014 – 2018 General Counsel and Chief Strategy Officer, JUMP Bikes 2009 – 2014 General Counsel, Trespa North America 2007 – 2009 Litigation Associate, Paul, Weiss, Rifkind, Wharton & Garrison LLP Education Avra holds a BA in History and Literature from Harvard University and a JD from Georgetown University Law Center.
Joshua Torrey is listed by SOSV as IT Manager.
Tushar Tomar is listed by SOSV as Workshop Manager.
Yash Suryawansh is listed by SOSV as Mechatronics Engineer.
Sabriya Stukes is listed by SOSV as Partner, SOSV NY.
Tyler Shi is listed by SOSV as Mechanical Engineer.
Catherine Seo is listed by SOSV as Corporate Investor Relations & Analyst, SOSV SF / Associate, SOSV SF.
Bethany Watson is listed by SOSV as Program Manager, SOSV NY.
Susan Schofer is listed by SOSV as Partner & Chief Science Officer.
Wasim Salih is listed by SOSV as Industrial Designer.
Marc Rose is listed by SOSV as Engineer, HAX.
Anuraj Rawat is listed by SOSV as Investment Analyst, HAX.
Charles Peter is listed by SOSV as Director of Mechanical Engineering.
Joe Oliveira is listed by SOSV as Workshop Manager, HAX.
Rian O’Neill is listed by SOSV as Fund Analyst.
Melanie O’Connor is listed by SOSV as Investor Relations Associate.
Edwina O’Brien is listed by SOSV as Assistant Accountant, SOSV.
Maria O’Brien is listed by SOSV as Senior Operating Partner.
John O’Brien is listed by SOSV as Global Director of IT.
Mark Nolan is listed by SOSV as Finance Manager.
Donnacha Murphy is listed by SOSV as Operations Analyst.
Siobhán Murphy is listed by SOSV as General Counsel.
Finance Director at SOSV in Cork, overseeing financial, compliance and tax affairs and supporting portfolio companies with financial planning.
Michael Moon is listed by SOSV as Director of Electronic Engineering.
Stephen McCann is listed by SOSV as General Partner & Chief Financial Officer, SOSV.
Sandra Manning is listed by SOSV as Head of HR.
Carrie Mandy is listed by SOSV as Investment Analyst.
Executive Assistant supporting SOSV's Managing General Partner; previously worked in music education and human resources.
Former private-equity M&A lawyer and corporate legal consultant, with experience advising healthcare startups on transactions, intellectual property and data privacy. Leads Mendea Technologies.
Prof Jon Grant is Professor of Psychiatry at University of Chicago and director of a clinic and research lab on addictive, compulsive and impulsive disorders.
Dr Susanne Stuffers is CEO and Founding Partner of p53. She holds an M.D. degree from the Erasmus University Rotterdam, Netherlands, and a Ph.D. degree in cancer biomedicine from the Norwegian Radiumhospital. She gained broad experience in healthcare and life sciences, covering the sector from several angles. Susanne was a management consultant in health care (public and private) and life sciences at EY, served in medical and commercial roles in the pharmaceutical industry (Novartis), and has clinical practice as a resident in oncology. She worked with Arctic Securities as an equity analyst covering the healthcare sector, before joining forces with T.D. Veen to co-found and lead p53.
After graduating from Loughborough University in 1997, Julia joined PriceWaterhouseCoopers and qualified as a Chartered Accountant in 2001. For the last 15 years, as the founder and Managing Director of Archangel Accounting Ltd, Julia has provided tailor-made services to many companies, including IPO and fundraising support. Julia Jones provides fractional finance leadership to TRIMTECH. A Loughborough graduate and chartered accountant trained at PwC, she founded Archangel Accounting and supports biotechnology companies with finance operations, fundraising and IPO preparation. This fractional role is distinct from any other retained company finance affiliation.
Hannah is Communications Officer at Serenatis Bio, where she works across scientific communication, investor outreach, and research analysis in support of the company’s mission to develop novel therapies for OCD. With an academic background in mathematics, physics, and history, alongside experience in both qualitative and quantitative research, she brings a strong analytical and interdisciplinary perspective to her work. Being passionate about science communication and making complex ideas accessible, she contributes to Serenatis Bio’s social media, website, investor engagement, and scientific literature reviews.
Reet is an AI Engineer at Serenatis Bio, where she applies artificial intelligence and computational methods to accelerate and optimise the discovery of novel therapies for OCD. With formal training in biotechnology, bioinformatics, and computational biomedical engineering, she holds research experience in AI-driven drug discovery and healthcare technologies. Reet is also a named author on several scientific publications. Together, this experience contributes to Serenatis Bio’s precision approach to developing more targeted therapies for OCD.
David Cavalla has 35 years experience in various senior scientific and commercial roles within the pharmaceutical industry. Previously he was founder and CEO of Arachnova Ltd, a company focused on therapeutic switching; previous affiliations included Glaxo Group Research Ltd and Napp Research Centre.
Nick Sireau is an OCD advocate and also co-founder and Chair of Orchard OCD, a medical charity that funds academic research into OCD. Nick runs a support group for people with severe OCD where he lives in Cambridge, UK.
Woojung Lee is listed by SOSV as Associate.
Manvendra Kumar is listed by SOSV as Senior Mechanical Engineer.
Ian Koss is listed by SOSV as Lead Software Developer.
Kelly Kirkpatrick is listed by SOSV as Partner & Director of Investor Relations.
Ji Ke is listed by SOSV as Partner & CTO, HAX.
Daniel Kavanagh is listed by SOSV as Finance Manager.
General Partner at SOSV SF and physician-entrepreneur with more than 25 years of experience leading life-science startups.
Meghan Hind is listed by SOSV as Data & Business Analyst.
Brit Harley is listed by SOSV as Office Manager.
Arvind Gupta is listed by SOSV as Venture Advisor.
Andrew Gollach is listed by SOSV as Partner.
Bella Giordano is listed by SOSV as Administrative Assistant to SOSV’s Managing General Partner.
Alex Firestine is listed by SOSV as Analyst.
William Farah is listed by SOSV as Legal Counsel.
Sophie Dorgan is listed by SOSV as Legal Operations Analyst.
Pia Doran is listed by SOSV as Office Manager.
Communications and marketing advisor at SOSV, previously its senior operating partner.
Jackie Della Torre is listed by SOSV as Events & Community Manager.
Cassandra De Jesus is listed by SOSV as Facilities Coordinator.
Kira Colburn is listed by SOSV as Director of Communications.
Tina Chen is listed by SOSV as Operations Assistant.
Sierra Brooks is listed by SOSV as Senior Scientist & Analyst, IndieBio / Associate, IndieBio.
Po Bronson is listed by SOSV as General Partner & Managing Director, SOSV SF.
Hugh Bowen is listed by SOSV as Associate, SOSV / Associate, SOSV SF.
Madeline Behr is listed by SOSV as Principal, Investor Relations & Capital Formation, SOSV.
Parsa Amiri is listed by SOSV as Investment Analyst.
Norm Amandi is listed by SOSV as Video Content Director.
Selin Altinok is listed by SOSV as Investment Analyst.
Ghaith Alghamdi is listed by SOSV as Principal.
Toshi Akashige is listed by SOSV as Laboratory & Safety Manager.
Supriya Agarwal is listed by SOSV as Director of Marketing, Data & AI.
Asher joined Oxford Technology in 2024. He has a degree in Linguistics from the University of Oxford and experience performing numerical calculations in a range of programming languages.
Mateusz joined Oxford Technology in 2022. He has a civil, structural, and mechanical engineering background and obtained a DPhil (PhD) degree in advanced shape-shifting mechanisms from the University of Oxford. At Oxford, Mateusz worked with and advised technology startups, mainly in robotics, aerospace, and agriculture.
Bijan founded and exited InCa, a FGPA Prototyping company seeded by Oxford Technology back in the 1980s. He then spent two decades with Synopsys, helping grow it from 300 to 13,000 employees. Bijan missed working with start-ups, however, and now consults our companies on the US market. He is also currently the CEO of Mach42.
Lucius raised his first science and technology seed fund in 1983, after founding and exiting his first business. He has been investing in science startups ever since. He has a degree in Economics and Engineering from Oxford and an MBA from Harvard Business School. In 2003 he was awarded an OBE for services to business.
Data scientist developing neuro-inclusive software and assessment tools at ThinkDivergent.
Former NHS consultant with experience leading health-system reforms and advocating for inclusive neurodevelopmental care.
Biomedical researcher and clinician working on glioblastoma biology and cancer-cell migration; scientific co-founder of Migration Biotherapeutics.
Medical-device entrepreneur with expertise in imaging and regulatory strategy; commercial co-founder of Migration Biotherapeutics.
Consultant neurosurgeon and inventor of Neurolase’s surgical guidance system. Trained at Oxford, Cambridge, Imperial College London and UCL; leads technology development and clinical implementation.
Healthcare entrepreneur with experience in M&A and healthcare consulting. Leads Neurolase’s product development, partnerships, investor relations and commercial expansion.
Ro Gardner, Operations Adviser, expert in logistics, management, governance, business administration, and communications with a specific focus on companies at earlier stages of growth.
Toby Wilson Waterworth, Business Adviser, an internationally experienced Board member and senior executive with broad experience of developing biopharmaceutical and healthcare companies as well as navigating regulatory pathways to bring drugs to market, with a track record of previous success.
Martyn Postle is a Senior Director who has worked in and for the life science sector for over 40 years with a network in Europe, USA, Asia, and the Middle East. He has a track record of building successful businesses from the ground up.
Prof Claire Thompson, formulation expert and entrepreneur, supporting drug development through multiple milestones and ensuring translational viability.
Dr Shaun McNulty is a biochemist with over 25 years’ experience leading drug discovery, including 12 years as a biotechnology CSO. He has led programmes from hit discovery through candidate selection and clinical development. Shaun brings deep expertise in preclinical development, translational strategy and building high-performing global R&D units to support the development of novel therapies for neurological disease.
Dr John Skidmore, Chief Scientific Officer, Alborada Drug Discovery Institute at Cambridge, offers advice in medicinal chemistry and biodistribution assessments of pharmaceuticals.
Dr Brotchie, Parkinson’s Adviser, a co-founder and Chairman of Atuka Inc specialising in advanced preclinical Parkison’s models and translatability of disease mechanisms from models to clinic. He has led translational research that supported the advancement of 14 drug candidates to clinical studies.
Prof Grazia Spillantini, Parkinson’s Adviser and Professor of Molecular Neurology at University of Cambridge, is a pioneer of alpha-synuclein research that described how abnormal protein misfolding contributes to cell dysfunction and demise in Parkinson’s.
Prof Tansey, Parkinson’s Adviser, James A. Caplin MD, Chair in Alzheimer’s Disease, Professor of Neurology, Director of Neuroimmunology Research & Executive Associate Director of Education at Stark Neuroscience Research Institute, Indiana University School of Medicine. She is an expert in the inflammatory aspects driving Parkinson’s disease.
Dr Lewis Pennicott is a medicinal chemist with over 20 years’ experience across biotech, academic and CRO environments. He has led small-molecule programmes from hit discovery through to lead optimisation and candidate selection. Lewis brings deep expertise in complex synthesis, SAR-driven design and collaborative drug discovery to support the development of novel therapies for neurological disease.
Dr Shawn Manning’s career spans >30 years in life sciences overseeing multiple aspects of corporate strategy planning, governance, and operations management. He brings experience in financial planning and modelling with a focus on medical research.
Stephen Grant, Chairman, executive level international leader with experience in pharma, biotech, and life science, overseeing all stages of business growth from early fundraising to successful exit strategies.
Dr Nat Hastings has over 10 years of experience in clinical research and bioengineering at the University of Cambridge with specialist knowledge in astrocytic network biology and Parkinson’s disease. Grant management and equity fundraise.
Natalie has a PhD in medical science (ophthalmology and inflammation), then biotechnology and healthtech startup operator across Canada, UK, EU and globally, then venture building and investing, culminating in ~15 years of 360 healthcare experience. She can be found sometimes lecturing, advising and consulting for cool and impactful organisations like WHO, European Innovation Council, Hult Prize, and UK Parliament.
Martin is a Chartered Chemical Engineer with extensive experience at bp, recognised for a passion for commercialising technology and a talent for turning ideas into action through a collaborative approach. His career reflects a strong track record in corporate venturing, digital strategy development, and technology incubation, consistently delivering results through influence.
Mark is a passionate and purpose-driven leader in life sciences and health tech, with three decades of experience building and scaling organisations that use data and innovation to improve lives. A founder, investor, and advisor, he has led businesses with revenues exceeding £1BN, raised more than £250M in capital, and delivered multiple successful exits. Known for his collaborative approach and ability to unite industry, academia, and the NHS, Mark has shaped partnerships and platforms that advance real-world data, genomics, and digital health globally. Guided by empathy, creativity, and commercial discipline, he is committed to developing purpose-led ventures and the next generation of health innovators.
Lily started her career at Ernst & Young (‘EY’), where she qualified as an accountant. She gained a wide range of experience working across many different sectors, including working on advisory projects with sporting clients such as World Rugby, Rugby Football Union, as well as working in M&A structuring with large private equity houses.
Kate has spent the past decade working with founders of early stage B2B startups, helping them to find product market fit and to scale. Her key areas of expertise include marketing and go-to-market strategies, building thriving B2B communities, and the people & culture aspects of team building.
Emilie has nearly a decade of experience in building and investing in university spinouts, as part of the Investment Committee at Parkwalk Advisors and previously at Oxford University Innovation, where she worked both in Investments and leading the Startup Incubator, managing over 80 ventures from inception to exit. She moved into technology transfer after 14 years as a research scientist, directing pioneering experiments in systems neuroscience in Oxford, Bordeaux and Hamburg. Emilie holds a PhD in Neuroscience from the University of Hamburg and an MBA from Warwick Business School, specialising in Strategy and Finance.
Eleanor joined Zinc in Oct 2019 to launch the new Zinc Academy. Most recently Eleanor was Director of the Good Lab, a radical innovation collaboration of 12 of the UK’s largest charities, looking to transform how they raise funds through venturing. Eleanor started her career as an anthropologist and documentary filmmaker, before landing in the world of start-ups in 2006, founding a technology company, LikeCube, which was acquired by Oakley Capital Private Equity and the Time Out Group, where she stayed for 5 years as Global Innovation Director.
David is a deeptech investor, advisor, and entrepreneur with extensive global experience. As CEO of Sonosine and co-founder of Spectroma, he has led the development of pioneering medical technologies. He has worked extensively with private equity firms and venture capital investors globally, supporting entrepreneurs, scientific founders, and management teams with strategic insight, operational expertise, and mentorship. David holds an MSc in Industrial Engineering with a specialisation in Mechanical Engineering.
Claire is a qualified accountant with extensive experience building and scaling functions across startups and venture funds. Before joining Zinc, she held senior roles at Entrepreneur First and a range of high-growth technology businesses.
Ella is a former Strategy Director at IPG Mediabrands, one of the world’s largest media agencies, working with global leading brands. She is the Co-Founder of NewCo UK, which connects the most successful large corporates with the most innovative start-ups in the UK. Ella started her career as an engineer in Tel Aviv’s hi tech aerospace industry, before becoming a consultant to tech firms.
Paul is a former partner at KPMG and the global head of public services and government. In his career, he has been Head of the Number 10 Policy Unit, as well as working in the media, education, transport and urban regeneration sectors. Paul is a Visiting Professor at the London School of Economics & Political Science and was a Director of Bethnal Green Ventures and a Non-Executive Director of the Cabinet Office.
Leads neuroscience and mental-health research and diligence at Dragonfly 44 Capital. Previously worked in neuroscience equity research at H.C. Wainwright, M&A at atai Life Sciences and clinical research at Memorial Sloan Kettering Cancer Center. Holds a master’s degree in bioengineering from Cornell University.
Neuroscience venture investor and founder and managing partner of Dragonfly 44 Capital, a brain-health investment bank. Holds a Master of Business and Science in Biotechnology and Genomics from Rutgers University and a bachelor’s degree in biological sciences.
SV Health Investors biotechnology vice president with immunology research and company formation experience; previously led business development and strategy at Xilio Therapeutics and worked at L.E.K. Consulting.
Andy Richards is listed by Cambridge Innovation Capital as advisory panel member. Life-sciences entrepreneur involved in Chiroscience and healthcare boards; his published background includes neuroscience and digital mental-health businesses. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets. Andy Richards is publicly named by Cambridge Angels in its selected individual-member directory. Membership is an angel-network affiliation: individual investment choices are independent, and membership alone does not prove personal investment in any portfolio company.
Jonathan Tobin is partner at Brandon Capital. He joined the London investment team in2021 after Arix Bioscience and Touchstone Innovations. His educational background spans Oxford biology, UCL molecular medicine and an Imperial MBA, alongside Cancer Research UK postdoctoral work. His established Cancer Research Horizons affiliations are preserved. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.
Former Arnold & Porter Kaye Scholer partner overseeing IQT legal affairs.
Electrical-engineering researcher and former Booz Allen Hamilton technology adviser.
Leads U.S. investments; joined IQT in 2017.
Former IQT Chief People Officer and Council on Foundations COO.
Directs overseas investments; previously led IQT’s portfolio success function.
Former Point72 Private Investments managing partner and U.S. Marine.
Marketing and operations leader who joined IQT in 2012.
Biochemistry and molecular-biophysics researcher; previously a Fluidigm senior scientist.
Joined IQT in 2003; previously its EVP and CFO.
Former InterWest general partner; joined IQT in 2006.
Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: New York Angels. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation. Exact NewYorkAngels currentJune2026newsletter explicitlyidentifies TomHirschfeldAiMdeal lead, corroborating existingAiMboardobserveridentity.
John Rolston is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Brigham and Women’s Hospital, Boston; also Harvard neurosurgeon and AiM Medical Robotics adviser.
Machine-learning engineer and co-founder of Quantum Boost, identified as CTO in its 2023 publications. His public professional profile now lists Magic; a current CTO role at Quantum Boost is not inferred.
Materials-science and quantum-technology researcher who co-founded Quantum Boost with Kacper Kielak. The company identified him as CEO in its 2023 publications.
Aerospace and communications industry professional with managing-director experience, listed on Kurs Orbital’s team page.
Rendezvous and proximity operations specialist with experience in the KURS docking systems. Also listed as Vadim Vasiliev on the company team page; appointed to CONFERS’ board in 2025.
Space entrepreneur and former chairman of the State Space Agency of Ukraine. Co-founder and chief executive of Kurs Orbital.
Defense and intelligence professional with experience at SAIC, Sandia National Labs and Raytheon and as a senior national security adviser to the US Congress. Published by Acequia as Venture Partner, Intel & Defense; identity kept separate from the same-name IQT life-sciences investor.
Venture capital investor since 1996 who runs Chalfen Ventures as a solo investor backing early-stage European software founders.
Former founding engineer at 11x and co-founder of Tracelight.
Former Jane Street engineer and co-founder of Tracelight.
Former McKinsey consultant and Entrepreneur First team lead. Co-founded Tracelight in 2024.